# Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

> **NCT05067634** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **SK Life Science, Inc.** · enrollment: 140 (estimated)

## Conditions studied

- Partial Epilepsy

## Interventions

- **DRUG:** Xcopri

## Key facts

- **NCT ID:** NCT05067634
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-14
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05067634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05067634, "Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05067634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*